<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164875">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987297</url>
  </required_header>
  <id_info>
    <org_study_id>APL2012</org_study_id>
    <nct_id>NCT01987297</nct_id>
  </id_info>
  <brief_title>Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL</brief_title>
  <official_title>Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective randomized study for patients with newly diagnosed acute promyelocytic
      leukemia, patients will be randomized into two groups which received retinoic acid and
      arsenic trioxide based treatment versus retinoic acid and chemotherapy based regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective randomized study for patients with newly diagnosed acute promyelocytic
      leukemia. For induction, all patients will be randomized into two groups which received
      treatment composed of retinoic acid combined with arsenic trioxide versus retinoic acid
      combined with chemotherapy. For consolidation, the experimental group recieved 2 cycles of
      ATRA+arsenic and control group recieved two cycles of ATRA+idarubicin or daunorubicin. After
      consolidation, all patients achieved molecular remission will recieved 5 cycles of
      maintenance treatment with ATRA and arsenic. In case of intermediate or high-risk disease,
      cytarabine will be add for consolidation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>arsenic associated toxicity</measure>
    <time_frame>5 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>ATRA+Arsenic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received treatment with retinoic acid and arsenic trioxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATRA+chemo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients recieved retinoic acid and chemotherapy with idarubicin or daunorubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRA+arsenic</intervention_name>
    <description>experimental</description>
    <arm_group_label>ATRA+Arsenic</arm_group_label>
    <other_name>retinoic acid + arsenic trioxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRA+chemo</intervention_name>
    <description>control</description>
    <arm_group_label>ATRA+chemo</arm_group_label>
    <other_name>retinoic acid + idarubicin or daunorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly-diagnosed patients with acute promyelocytic leukemia via cytogenetics and
             molecular assay

          -  Age: 18-65

          -  Hepatic/renal function: Bil≤35μmol/L，AST/ALT less than 2Xnormal range, Cr 150μmol/L

          -  Normal cardial function

          -  Informed consent

        Exclusion Criteria:

          -  Relapsed patients

          -  Known history of arsenic allergy

          -  QT interval &gt;450ms

          -  Other malignanct disease

          -  Pregnant patients

          -  Patients with mental illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-min Li, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU</last_name>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU</last_name>
      <email>hujiong@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jun-min Li, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Deaprtment of Hematology</investigator_title>
  </responsible_party>
  <keyword>arsenic</keyword>
  <keyword>acute promyelocytic leukemia</keyword>
  <keyword>outcome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
